BlackRock Amends Ocular Therapeutix Stake on Dec 31, 2023
Ticker: OCUL · Form: SC 13G/A · Filed: Jan 31, 2024 · CIK: 1393434
| Field | Detail |
|---|---|
| Company | Ocular Therapeutix, Inc (OCUL) |
| Form Type | SC 13G/A |
| Filed Date | Jan 31, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns a chunk of Ocular Therapeutix, good sign for the stock!**
AI Summary
BlackRock, Inc. filed an amended SC 13G/A on January 31, 2024, disclosing its ownership in Ocular Therapeutix, Inc. as of December 31, 2023. This filing indicates that BlackRock, a major institutional investor, continues to hold a significant stake in the pharmaceutical company. For investors, this means a large, influential fund manager maintains confidence in Ocular Therapeutix, which can be a positive signal for the stock's stability and future prospects.
Why It Matters
This filing shows BlackRock's continued, significant investment in Ocular Therapeutix, signaling institutional confidence that can influence other investors and potentially stabilize the stock price.
Risk Assessment
Risk Level: low — This filing indicates stable institutional ownership, which generally reduces volatility and risk for the stock.
Analyst Insight
An investor should note BlackRock's continued presence as a significant shareholder, which suggests a level of institutional endorsement. While not a direct buy signal, it indicates stability and warrants further research into Ocular Therapeutix's fundamentals and BlackRock's broader investment strategy.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- Ocular Therapeutix, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 31, 2024 (date) — the filing date of the SC 13G/A amendment
- 67576A100 (other) — the CUSIP number for Ocular Therapeutix Common Stock
Forward-Looking Statements
- BlackRock will likely maintain a significant stake in Ocular Therapeutix for the foreseeable future. (BlackRock, Inc.) — medium confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under Rule 13d-1(b) of the Securities Exchange Act of 1934.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., a major institutional investment manager.
What is the subject company whose securities are being reported?
The subject company is Ocular Therapeutix, Inc., a pharmaceutical preparations company.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of Ocular Therapeutix, Inc. is 67576A100.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 31, 2024 regarding OCULAR THERAPEUTIX, INC (OCUL).